Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 258 results found since Jan 2013.
Influence of nNav1.5 on MHC class I expression in breast cancer
In this study, we associate it with the elevation of 'neonatal' Nav1.5 (nNav1.5) mRNA expression in the aggressive type of human breast cancer cells. Using real-time PCR, lower expression of TAP1 (by - 4.83-fold), which is a part of the MHC class I antigen processing machinery (APM) pathway component, in contrast to the greater expression of nNav1.5 (by 3.76-fold), along with other metastatic markers, MMP1 (by 57.48-fold) and fibronectin (by 2.88-fold) in aggressive human breast cancer cell line, MDA-MB231 were obtained. Subsequent knockdown of nNav1.5 (by 52.6%) in MDA-MB-231 via siRNA-SCN5A resulted in downregulation of ...
Source: Journal of Biosciences - July 27, 2021 Category: Biomedical Science Authors: Ahmad Hafiz Murtadha Irfan Irsyad Mohd Azahar Nur Aishah Sharudin Ahmad Tarmizi Che Has Noor Fatmawati Mokhtar Source Type: research
B7-H3 on breast cancer cell MCF7 inhibits IFN- γ release from tumour-infiltrating T cells
Pathol Res Pract. 2021 May 5;224:153461. doi: 10.1016/j.prp.2021.153461. Online ahead of print.ABSTRACTB7-H3 is a type I membrane protein that has contradictory co-stimulatory and co-inhibitory effects in adaptive and anti-tumour immunity. B7-H3 is up-regulated in many malignant tumours, including breast cancer. Therefore, we hypothesise that B7-H3, which has an immunosuppressive role, suppresses anti-tumour immunity. The aim of this study was to clarify the role of B7-H3 in the tumor microenvironment in breast cancer, explore the possibility of B7-H3 as a target for clinical immunotherapy, and provide reference for clinic...
Source: Pathology, Research and Practice - July 15, 2021 Category: Pathology Authors: Lili Shao Qiongzhu Yu Rui Xia JiaYu Zhang Siyi Gu Daojiang Yu Zhixiang Zhuang Source Type: research
B7-H3 on breast cancer cell MCF7 inhibits IFN-gamma release from tumour-infiltrating T cells
Pathol Res Pract. 2021 May 5;224:153461. doi: 10.1016/j.prp.2021.153461. Online ahead of print.ABSTRACTB7-H3 is a type I membrane protein that has contradictory co-stimulatory and co-inhibitory effects in adaptive and anti-tumour immunity. B7-H3 is up-regulated in many malignant tumours, including breast cancer. Therefore, we hypothesise that B7-H3, which has an immunosuppressive role, suppresses anti-tumour immunity. The aim of this study was to clarify the role of B7-H3 in the tumor microenvironment in breast cancer, explore the possibility of B7-H3 as a target for clinical immunotherapy, and provide reference for clinic...
Source: Cell Research - July 15, 2021 Category: Cytology Authors: Lili Shao Qiongzhu Yu Rui Xia JiaYu Zhang Siyi Gu Daojiang Yu Zhixiang Zhuang Source Type: research
B7-H3 on breast cancer cell MCF7 inhibits IFN- γ release from tumour-infiltrating T cells
Pathol Res Pract. 2021 May 5;224:153461. doi: 10.1016/j.prp.2021.153461. Online ahead of print.ABSTRACTB7-H3 is a type I membrane protein that has contradictory co-stimulatory and co-inhibitory effects in adaptive and anti-tumour immunity. B7-H3 is up-regulated in many malignant tumours, including breast cancer. Therefore, we hypothesise that B7-H3, which has an immunosuppressive role, suppresses anti-tumour immunity. The aim of this study was to clarify the role of B7-H3 in the tumor microenvironment in breast cancer, explore the possibility of B7-H3 as a target for clinical immunotherapy, and provide reference for clinic...
Source: Pathology, Research and Practice - July 15, 2021 Category: Pathology Authors: Lili Shao Qiongzhu Yu Rui Xia JiaYu Zhang Siyi Gu Daojiang Yu Zhixiang Zhuang Source Type: research
PD-1-siRNA Delivered by Attenuated Salmonella Enhances the Antitumor Effect of Chloroquine in Colon Cancer
This study suggests that the combined application of PD-1-based immunotherapy and anti-cancer drugs has become a new expectation for clinical treatment of colorectal cancer.
Source: Frontiers in Immunology - July 6, 2021 Category: Allergy & Immunology Source Type: research
Regulation of CD47 expression by interferon-gamma in cancer cells
Transl Oncol. 2021 Jun 22;14(9):101162. doi: 10.1016/j.tranon.2021.101162. Online ahead of print.ABSTRACTThe anti-phagocytosis signal, CD47, prevents phagocytosis when it interacts with signal-regulatory protein alpha (SIRPα) on macrophages. Given the vital role of CD47 in immune response, further investigation on the regulation of CD47 in tumor microenvironment is needed. Herein, we identified that interferon-gamma (IFN-γ), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as we...
Source: Translational Oncology - June 25, 2021 Category: Cancer & Oncology Authors: Zi-Han Ye Xiao-Ming Jiang Mu-Yang Huang Yu-Lian Xu Yu-Chi Chen Luo-Wei Yuan Can-Yu Huang Wei-Bang Yu Xiuping Chen Jin-Jian Lu Source Type: research
ASAP Tailoring the Architecture of Cationic Polymer Brush-Modified Carbon Nanotubes for Efficient siRNA Delivery in Cancer Immunotherapy
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.1c02627
Source: ACS Applied Materials and Interfaces - June 25, 2021 Category: Materials Science Authors: Danyang Li, Momina Ahmed, Anisah Khan, Lizhou Xu, Adam A. Walters, Bele ́n Ballesteros, and Khuloud T. Al-Jamal Source Type: research
Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
In this study, we develop PDDS{polyethylene glycol-b-asparaginate(diethylenetriamine-vorinostat), (PEG-b-P[Asp(DET-SAHA)n] PPDS)}encapsulating siRNA-PD-L1to provide micelles siRNA-PD-L1-loaded micelles (siRNA@PPDS). Transmission electron microscope (TEM) images demonstrate that siRNA@PPDS micelles presented spherical morphology with a size of about 120 nm; hydrodynamic data analysis indicates pH sensitivity of siRNA@PPDS micelles. The experiments reveal that siRNA@PPDS micelles could be well uptaken by the tumor cells to silence the expression of PD-L1 protein in a dose-dependent manner; compared with the free SAHA, the SA...
Source: Drug Delivery - May 26, 2021 Category: Drugs & Pharmacology Authors: Fengkun Lu Lei Hou Sizhen Wang Yingjie Yu Yunchang Zhang Linhong Sun Chen Wang Zhiqiang Ma Feng Yang Source Type: research
WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer
Conclusions: These data revealed that targeting WDR5 suppressed proliferation, enhanced apoptosis, chemosensitivity to cisplatin and immunotherapy in PCa. Therefore, our findings provide insight into OICR-9429 is a multi-potency and promising therapy drug, which improves the antitumor effect of cisplatin or immunotherapy in PCa.
Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Qianghua Zhou, Xu Chen, Haixia He, Shengmeng Peng, Yangjie Zhang, Jingtong Zhang, Liang Cheng, Sen Liu, Ming Huang, Ruihui Xie, Tianxin Lin, Jian Huang Tags: Research Paper Source Type: research
pH/ATP cascade-responsive nano-courier with efficient tumor targeting and siRNA unloading for photothermal-immunotherapy
Publication date: April 2021Source: Nano Today, Volume 37Author(s): Xian Tang, Qinglin Sheng, Chaoqun Xu, Man Li, Jingdong Rao, Xuhui Wang, Yang Long, Yuan Tao, Xuan He, Zhirong Zhang, Qin He
Source: Nano Today - February 11, 2021 Category: Nanotechnology Source Type: research
Hybrid Micelles Codelivering Shikonin and IDO-1 siRNA Enhance Immunotherapy by Remodeling Immunosuppressive Tumor Microenvironment
Publication date: Available online 2 February 2021Source: International Journal of PharmaceuticsAuthor(s): Ji Li, Ming Zhao, Yunhua Xu, Xiaoyun Hu, Yinghui Dai, Dongkai Wang
Source: International Journal of Pharmaceutics - February 2, 2021 Category: Drugs & Pharmacology Source Type: research
Cancers, Vol. 13, Pages 166: Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells
Conclusion: HuR-NP exhibited antitumor activity in melanoma cells independent of their oncogenic B-RAF mutational status. Additionally, combinatorial therapy incorporating MEK inhibitor holds promise in overriding MITF-mediated drug resistance in melanoma.
Source: Cancers - January 6, 2021 Category: Cancer & Oncology Authors: Rebaz Ahmed Ranganayaki Muralidharan Akhil Srivastava Sarah E. Johnston Yan D. Zhao Suhendan Ekmekcioglu Anupama Munshi Rajagopal Ramesh Tags: Article Source Type: research
